Ultimately, the goal is ensuring that innovative therapies reach patients without unnecessary delay
According to the 2021 review, Exenatide XR had the lowest rate of gastrointestinal side effects, while semaglutide injections were associated with the highest rate of these side effects
Retatrutide is currently in Phase 3 clinical trials and is not FDA approved yet
Eligibility, response, side effects, and outcomes vary
People in the field have questioned if there was anything GLP-1 drugs couldnt do
Common side effects include nausea and vomiting (slightly more common with the pill version), diarrhoea and/or constipation and abdominal discomfort, but these generally settle once people get used to the medicine